These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 20606683)
1. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Henry NL; Pchejetski D; A'Hern R; Nguyen AT; Charles P; Waxman J; Li L; Storniolo AM; Hayes DF; Flockhart DA; Stearns V; Stebbing J Br J Cancer; 2010 Jul; 103(3):291-6. PubMed ID: 20606683 [TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342 [TBL] [Abstract][Full Text] [Related]
3. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis. Roberts K; Rickett K; Greer R; Woodward N Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297 [TBL] [Abstract][Full Text] [Related]
4. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297 [TBL] [Abstract][Full Text] [Related]
5. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123 [TBL] [Abstract][Full Text] [Related]
6. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978 [TBL] [Abstract][Full Text] [Related]
7. A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11. Stearns V; Jegede OA; Chang VT; Skaar TC; Berenberg JL; Nand R; Shafqat A; Jacobs NL; Luginbuhl W; Gilman P; Benson AB; Goodman JR; Buchschacher GL; Henry NL; Loprinzi CL; Flynn PJ; Mitchell EP; Fisch MJ; Sparano JA; Wagner LI Clin Cancer Res; 2024 Jul; 30(13):2709-2718. PubMed ID: 38640040 [TBL] [Abstract][Full Text] [Related]
8. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms. Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476 [TBL] [Abstract][Full Text] [Related]
9. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817 [TBL] [Abstract][Full Text] [Related]
10. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms. Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166 [TBL] [Abstract][Full Text] [Related]
11. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806 [TBL] [Abstract][Full Text] [Related]
12. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Lintermans A; Laenen A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P Ann Oncol; 2013 Feb; 24(2):350-355. PubMed ID: 23038762 [TBL] [Abstract][Full Text] [Related]
13. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687 [TBL] [Abstract][Full Text] [Related]
14. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Bao T; Cai L; Giles JT; Gould J; Tarpinian K; Betts K; Medeiros M; Jeter S; Tait N; Chumsri S; Armstrong DK; Tan M; Folkerd E; Dowsett M; Singh H; Tkaczuk K; Stearns V Breast Cancer Res Treat; 2013 Feb; 138(1):167-74. PubMed ID: 23393007 [TBL] [Abstract][Full Text] [Related]
15. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827 [TBL] [Abstract][Full Text] [Related]
16. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. Hertz DL; Douglas JA; Miller RM; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM Support Care Cancer; 2022 Oct; 30(10):8059-8067. PubMed ID: 35776183 [TBL] [Abstract][Full Text] [Related]
17. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230 [TBL] [Abstract][Full Text] [Related]
18. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676 [TBL] [Abstract][Full Text] [Related]
19. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969 [TBL] [Abstract][Full Text] [Related]
20. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer. Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]